Sun Pharma’s (Pr) ILUMYA ™ (Tildrakizumab Injection) Now Available to Help Canadians With Moderate to Severe Plaque Psoriasis


  • ILUMYA is the first IL-23p19 inhibitor to complete a five-year study based on a pooled analysis of two phase 3 efficacy and safety extension trials in moderate to severe plaque psoriasis .
  • The results of the ILUMYA study showed that patients with moderate to severe plaque psoriasis maintained high and consistent levels of skin clearance and a sustained safety profile over five years of continuous treatment. In Canada, some patients involved in the study said they still had fair skin eight years later.
  • ILUMYA is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and is administered quarterly after the initial loading doses at week 0 and week 4, offering patients freedom and flexibility.

MUMBAI, India and BRAMPTON, ON, 28 October 2021 / CNW / – Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceuticals Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715), “Sun Pharma”, including including its subsidiaries and / or associated companies) is pleased to announce PrILUMYA â„¢ (injectable tildrakizumab), a treatment for adults living with moderate to severe plaque psoriasis, is now available in Canada.

“We are delighted to introduce this important biologic treatment to Canadians living with this common, inhibitory and often overlooked disease. This launch is an important milestone for Sun Pharma as we expand our dermatology portfolio into Canada,” noted Abhay Gandhi, CEO North America, Sun Pharma. “With five years of effective treatment for moderate to severe plaque psoriasis, ILUMYA demonstrates our commitment to providing innovative medicines to support patients’ lifestyle and physician choice. “

Plaque psoriasis is a chronic autoimmune disease that appears on the skin as red, raised areas of the skin covered with scaly white scales that can crack and bleed. It affects approximately one million Canadians.I Moderate to severe plaque psoriasis affects about 35% of patients.ii A major challenge is that many treatments stop working overtime and symptoms return. Long-term durability of treatment is an unmet need for many patients.

“Moderate to severe plaque psoriasis can make it difficult to feel comfortable in your own skin and finding an effective treatment can be as difficult as the disease itself,” said Dr. Melinda gooderham, certified dermatologist and medical director of the SKiN Center for Dermatology in Peterborough, Ontario. “Our patients need options for effective, sustainable and continuous treatment in Canada and ILUMYA will help meet this need. “

In a published peer-reviewed review of pooled reviews of the two trials reSURFACE 1 and reSURFACE 2, the data show that most patients on ILUMYA maintained a response and a reassuring safety profile over 5 years of treatment.

In patients treated with ILUMYA 100 mg, almost nine out of 10 patients maintained their response until the fifth year.iii ILUMYA 100 mg was well tolerated in the phase 3 trials. The three adverse reactions that occurred more frequently than placebo and ≥ 1% in clinical trials were upper respiratory tract infections (15.1% vs. 12 , 3%), injection site reactions (3.9% vs. 2.6%) and headache (3.2% vs. 2.9%).iv

In Canada, some patients involved in the study said they still had fair skin eight years later.

“I have patients who have been treated with ILUMYA for the past eight years, and have seen their skin improve at high levels of clearance and stay clear over the long term. As a result, their lives have gone downhill. also improved, “added Dr Gooderham.

“All my life I have struggled with moderate to severe plaque psoriasis, and have constantly alternated between creams and ointments which never worked and only increased my stress. Upon learning of ILUMYA, I thought I was running out of treatment options. “mentioned Ainsley Leween, patient with psoriasis. “Since I started using ILUMYA eight years ago my psoriasis has been under control.”

The Canadian Agency for Drugs and Technologies in Health (CADTH), through the Common Drug Review, has positively recommended to the provinces with which it treats that the product ILUMYA be reimbursed for patients with psoriasis in moderate to severe plaques, when prescribed by a dermatologist.v


Tildrakizumab, the active ingredient in ILUMYA, is a humanized IgG1 / k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL- receptor. 23, resulting in inhibition of release. pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy in Canada. ILUMYA has also been approved for use in United States, Japan and Australia, and under the ILUMETRI brand® in Europe.

For more information visit or call 1-833-388-0532.

TM – All brand names and trademarks are the property of their respective owners.

The references:

Statements contained in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward-looking statements” within the meaning of the law and applicable securities regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company assumes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unforeseen developments / circumstances after the date hereof.

About Sun Pharma Canada Inc.
Sun Pharmaceutical Industries Limited Expands Presence in Canada, bringing together the power of a global network with localized research and care to address the unmet needs of Canadian patients and healthcare providers.

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, is focused on providing innovative medicines in dermatology, providing better access and better support to patients.

The focus is on patients and providers, and the “Sun Pharma Passion is Clear”. Sun Pharma’s commitment to listen, act and care means that the team is able to meet distinct needs, provide personalized care, while filling significant gaps in treatment and quality of life.

Sun Pharma offers a wide variety of affordable drugs to Canadians. In collaboration with Taro Pharmaceutical Industries Ltd. (a subsidiary of Sun Pharma), these complementary companies bring together capabilities in specialty and niche segments coupled with a presence in the top 15 Canadian generics.

About Sun Pharmaceutical Industries Limited (CIN – L24230GJ1993PLC019050)
Sun Pharma is the world’s fourth largest generic specialty pharmaceutical company and india large pharmaceutical company. A vertically integrated company and skilled team enable it to provide high quality products trusted by customers and patients in over 100 countries around the world at affordable prices. Its global presence is supported by manufacturing facilities spanning 6 continents and endorsed by multiple regulatory agencies, coupled with a multicultural workforce comprising over 50 nationalities. Sun Pharma promotes excellence through innovation supported by strong R&D capabilities in several R&D centers, with investments of around 6 to 7% of its annual turnover in R&D. For more information, please visit and follow us on Twitter @SunPharma_Live.

SOURCE Sun Pharma Canada Inc.

For more information: Investors: Nimish Desai, Tel +91 22 4324 4324, Xtn 2778, Tel Direct +91 22 4324 2778, Mobile + 91-98203 30182, E mail [email protected]; Media: Gaurav Chugh, Tel +91 22 4324 4324, Xtn 5373, Direct Tel +91 22 4324 5373, Mobile +91 98104 71414, E-mail [email protected]; Canadian Media: Janet Metz, Mobile +1 609 389 3044, Email [email protected]


Leave A Reply